Loading patent…
AssigneeCel-Sci Corporation
InventorsDaniel H. Zimmerman, Roy Carambula, Harold Steiner, Eyal Talor, Tibor Glant, Katalin Mikecz
Estimating the term…
The invention is related to peptide constructs, i.e., polypeptides obtained by linking together two or more peptides based on or derived from different molecules, which are useful in the treatment or prevention of autoimmune diseases, specifically rheumatoid arthritis (RA) and compositions containing same, methods for producing same and methods for using same; wherein the peptide constructs have the formula P1-x-P2 where P1 is a peptide associated with autoimmune disease such as rheumatoid arthritis myocarditis, diabetes, and immune-mediated disease, which binds to an antigen receptor on a set or subset of T cells; P2 is a peptide which will cause a Th2 directed immune response by the set or subset of T cells to which the peptide P1 is attached or which will bind to a T cell receptor which will cause the set or subset of T cells to which the peptide P1 is attached to initiate, but not complete, an immune response causing the set or subset of T cells to undergo immunomodulation including but not restricted to anergy and apoptosis; and x is a direct bond or linker for covalently bonding P1 and P2. Whereas said treatment being of the individual itself or of ex vivo treatment of isolated DC and or with further labeling with drug, dye or radioisotope and administration back into the patient of the activated and possibly modified DCs for detection, identification, localization and treatment thereof.
1-3. (canceled)
A peptide for modulating an autoimmune response in a subject or for maturing dendritic cells, and or activating T cells, comprising a peptide construct having the formula P1-x-P2 or P2-x-P1, wherein
8-10. (canceled)
A composition comprising matured dendritic cells, the matured dendritic cells formed by contacting immature dendritic cells or monocytes with an effective amount of a peptide construct having the formula P1-x-P2 under conditions suitable for maturation of the immature dendritic cells to form the matured dendritic cells, wherein
17-29. (canceled)
(canceled)
(canceled)
35-36. (canceled)
(canceled)
40-59. (canceled)
A method for producing a matured dendritic cell population, comprising contacting or treating immature dendritic cells or monocytes with an effective amount of a peptide construct having the formula P1—X—P2 or P2—X—P1 under conditions suitable for maturation of dendritic cells or monocytes to form matured dendritic cells, wherein
64-386. (canceled)
Dependencies are inferred from the claim text.